Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIM447 and/or Ribociclib with Ruxolitinib in Myelofibrosis
NCT02370706Phase 1Completed
- Sponsor
- Novartis
- Start
- May 2015
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 1, open-label trial of PIM447 and ribociclib in myelofibrosis (MF) (6 arms), sponsored by Novartis. Primary endpoint: Incidence of dose limiting toxicities. Started May 2015; status: completed.
02
Drugs
PIM447ribociclib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT02370706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02370706.